|
gptkbp:instanceOf
|
gptkb:drug
antineoplastic agent
|
|
gptkbp:administeredBy
|
gptkb:rifampicin
gptkb:isoniazid
gptkb:pyrazinamide
|
|
gptkbp:ATCCode
|
J04AK02
|
|
gptkbp:brand
|
gptkb:Myambutol
|
|
gptkbp:CASNumber
|
74-55-5
|
|
gptkbp:chemicalFormula
|
C10H24N2O2
|
|
gptkbp:contraindication
|
optic neuritis
children under 5 years
|
|
gptkbp:discoveredBy
|
gptkb:Lederle_Laboratories
|
|
gptkbp:discoveredIn
|
1961
|
|
gptkbp:drugClass
|
antimycobacterial
|
|
gptkbp:eliminationHalfLife
|
3-4 hours
|
|
gptkbp:excretion
|
renal
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ethambutol
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits arabinosyl transferases
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
204.31 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
A (Australia)
|
|
gptkbp:proteinBinding
|
20-30%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
joint pain
optic neuritis
rash
visual disturbances
|
|
gptkbp:synonym
|
gptkb:ethambutol_hydrochloride
EMB
|
|
gptkbp:usedFor
|
treatment of tuberculosis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:rifampicin
|
|
gptkbp:bfsLayer
|
5
|